Local cooling techniques reduce immediate pain after subcutaneous heparin injection with SMD -0.64
Cooling Techniques May Reduce Pain From Heparin Injections
This meta-analysis of randomized controlled trials involving 807 participants found that local physical cooling techniques reduced immediate…
Local cooling techniques like ice packs or cold sprays may reduce immediate pain and bruising after heparin injections.
Deep learning for leukemia diagnosis faces fragmented research and limited multimodal integration in current literature
AI for leukemia diagnosis still fragmented, review finds
This scoping review evaluates deep learning techniques for leukemia detection across morphological, immunophenotyping, and molecular modalit…
A new review shows AI tools for leukemia diagnosis are promising but fragmented, with few using multiple data types.
Leukapheresis not clearly linked to lower 30-day mortality in AML with hyperleukocytosis
Leukapheresis Shows No Clear Early Death Benefit in AML
This meta-analysis of 1406 adults with AML and hyperleukocytosis found that leukapheresis was not clearly associated with lower 30-day morta…
A review of 1406 AML patients found leukapheresis did not clearly lower 30-day death risk. Evidence is weak.
Phage-induced mutations create fitness costs that enhance host immune clearance in bacterial infections
Bacterial infections may become easier to treat with phage therapy
This mini-review explores how bacteriophages can be used to create evolutionary traps for bacteria. The authors argue that phage-induced mut…
Bacteria trying to survive a virus attack might accidentally make themselves more vulnerable to your own immune system.
Mosunetuzumab plus polatuzumab vedotin achieved a 100% overall response rate in Japanese patients with LBCL
Trial shows promising results for relapsed large B-cell lymphoma
This Phase III randomized controlled trial analyzed a subgroup of 16 Japanese patients with relapsed or refractory large B-cell lymphoma. Th…
A new treatment combination showed a high response rate and longer progression-free survival for patients with a specific type of lymphoma.
Extracellular vesicles in RA: biomarkers and therapeutic vehicles, but clinical utility remains unproven
Extracellular Vesicles May Offer New Paths for Rheumatoid Arthritis
This mini-review examines extracellular vesicles (EVs) in rheumatoid arthritis, highlighting their cargo of citrullinated proteins, miRNAs, …
Small particles called extracellular vesicles may help doctors track and treat rheumatoid arthritis by signaling immune responses and carryi…
IV-PEG asparaginase compared to IM-EC in children with acute lymphoblastic leukemia
PEG-asparaginase shows lower toxicity in childhood leukemia trial
This Phase 3 randomized controlled trial evaluated intravenous PEG-asparaginase (IV-PEG) versus intramuscular native E. coli L-asparaginase …
A new trial finds that PEG-asparaginase may cause fewer side effects than standard treatment for children with leukemia.
Four specific miRNAs in extracellular vesicles satisfy high-tier causality for metabolic and inflammatory regulation
Extracellular Vesicles Show Potential for Managing Metabolic Health Conditions
This systematic review evaluates the role of extracellular vesicles (EVs) in managing obesity, type 2 diabetes, MASLD, and atherosclerosis. …
New research identifies specific molecules within extracellular vesicles that may play a role in managing obesity, diabetes, and liver disea…
FDA Approves Jakafi (ruxolitinib) for Steroid-Refractory Acute Graft-Versus-Host Disease
FDA approves Jakafi for acute graft-versus-host disease in patients 12 and older.
The FDA approved Jakafi (ruxolitinib) for treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12…
The FDA approved Jakafi (ruxolitinib) to treat acute graft-versus-host disease (aGVHD) in people aged 12 and older who do not respond to ste…
FDA Approves Inrebic (fedratinib) for Intermediate-2 or High-Risk Myelofibrosis
FDA approves new pill Inrebic for rare bone marrow cancer.
The FDA approved Inrebic (fedratinib) for adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis. The recommende…
The FDA approved Inrebic (fedratinib) for adults with a type of bone marrow cancer called myelofibrosis. It is a daily pill for patients wit…
FDA Approves Vonjo (pacritinib) for Myelofibrosis with Low Platelet Counts
FDA approves new drug Vonjo for rare bone marrow cancer with low platelets.
The FDA approved Vonjo (pacritinib) for adults with intermediate or high-risk primary or secondary myelofibrosis with platelet counts below …
The FDA approved Vonjo (pacritinib) for adults with myelofibrosis who have very low platelet counts. It helps reduce spleen size. This offer…
ctDNA and immune profiling offer a pathway toward individualized treatment for recurrent colorectal cancer
New tools help identify high risk of colorectal cancer relapse
This mini review explores ctDNA-guided surveillance, immune checkpoint blockade, and engineered cell therapies for patients with colorectal …
Doctors are using blood tests and immune profiling to better predict when colorectal cancer might return after treatment.